News & Events

The purpose of this Swiss-based joint venture, named BD/Medico GmbH, is to design and develop new pen injection devices. Pen injection devices are medical devices designed for the administration of parenteral drugs by the patients themselves. These devices incorporate auto-injecting and hidden needle designs to reduce patient anxiety and fear of injections. Future devices will include unique and proprietary technology utilizing intellectual property developed by Haselmeier GmbH and BD/Medico GmbH. Under the terms of this agreement, BD has worldwide rights for the sales and marketing of all injection devices developed by BD/Medico.

"The ongoing development and market introductions of new drugs requiring self-injection has increased the need for more advanced and patient-friendly injection devices," said Alexandre Conroy, Worldwide Vice President, BD Pharmaceutical Systems. "We believe that the joint venture between BD and Haselmeier represents a strong foundation to develop new devices that meet the evolving needs of both pharmaceutical companies and patients." For more information on BD self-injection devices click HERE.

Haselmeier is a privately held German manufacturer of medical devices, focusing on the area of self-injection technology. The company is located in Stuttgart, with manufacturing facilities in Buchen, Germany, and has ongoing supply agreements with many of the world's leading pharmaceutical manufacturers.

Becton, Dickinson and Company (NYSE: BDX) manufactures and sells a broad range of medical supplies and devices and diagnostic systems for use by health care professionals, medical research institutions and the general public. For its most recent fiscal year, the company reported revenues of $3.1 billion and net income of $236 million.